Innovations in Pharmaceutical Sciences Seminar Series
Virtually via Zoom
Reed F. Beall is a population health researcher who works largely with medicine patent, regulatory, and utilization data to investigate the long-term impacts of national and international policy decisions which aim to balance incentives between equitable drug innovation and equitable drug access. He is an Assistant Professor in Healthcare Policy in the Department of Community Health Sciences within the Cumming School of Medicine and at the O’Brien Institute for Public Health at the University of Calgary. He also serves as affiliated faculty for the Program on Regulation, Therapeutics, and the Law (PORTAL) based within the Division of Pharmacoepidemiology and Pharmacoeconomics at the Brigham and Women’s Hospital and Harvard Medical School. He has been invited to provide testimony on his research to the trilateral technical symposium of the World Health Organization, the World Intellectual Property Organization, and the World Trade Organization, as well as to the United Nations Secretary-General's High-Level Panel on Access to Medicines. Dr. Beall’s work has been published in Value in Health, Nature Biotechnology, Health Affairs, PLoS Medicine, and Social Science and Medicine, among others.
William Feldman is a pulmonologist, intensivist, and health services researcher at Harvard Medical School and Brigham and Women's Hospital, where he has joint appointments in the Division of Pharmacoepidemiology and Pharmacoeconomics and the Division of Pulmonary and Critical Care Medicine. He completed his undergraduate degree in philosophy at Duke University, his medical degree at the University of California San Francisco, his doctorate in political theory at the University of Oxford, and his master's in public health at the Harvard TH Chan School of Public Health. He was a Fulbright Scholar at the University of Haifa and a Zuckerman fellow at the Center for Public Leadership at Harvard Kennedy School. He completed training in Internal Medicine and Pulmonary and Critical Care Medicine at Brigham and Women's Hospital.
Dr. Feldman's research focuses on drug pricing, FDA regulation, pharmaceutical policy, and COPD outcomes. His work has appeared in the New England Journal of Medicine, the Journal of the American Medical Association, Health Affairs, and Lancet Respiratory Medicine. He currently serves as Co-Chair of the Ethics Committee and Associate Director of the Ethics Service at Brigham and Women's Hospital.
